| Alicia Broadway Swann, AUDIOLOGIST | |
|
541 Highway 80 W, Suite C, Clinton, MS 39056-4193 | |
| (601) 488-4189 | |
| (601) 488-4888 |
| Full Name | Alicia Broadway Swann |
|---|---|
| Gender | Female |
| Speciality | Audiologist |
| Location | 541 Highway 80 W, Clinton, Mississippi |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003004664 | NPI | - | NPPES |
| 00534872 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | A0955 (Mississippi) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Alicia Broadway Swann, AUDIOLOGIST 541 Highway 80 W, Auditory Processing Center, Clinton, MS 39056-4193 Ph: (601) 488-4189 | Alicia Broadway Swann, AUDIOLOGIST 541 Highway 80 W, Suite C, Clinton, MS 39056-4193 Ph: (601) 488-4189 |
News Archive
Colorectal carcinoma is one of the most common cancers in the world. Approximately one in four of these patients have metastases at diagnosis, liver being the most common site involved. Although historically it was considered that liver metastases meant a very poor prognosis, today, due to improved systemic therapy, many patients will be candidates for local hepatic treatments such as surgery or less aggressive radiofrequency ablation.
Researchers at Yale University School of Medicine found that SARS-CoV-2 viral loads in saliva are higher for patients with associated risk factors and underlying conditions that lead to severe COVID-19 and death. Thus, saliva viral loads could be used to predict disease severity.
A new study finds that certain changes in blood vessels in the eye's retina can be an early warning that a person is at increased risk for glaucoma, an eye disease that slowly robs people of their peripheral vision.
Hyperion Therapeutics, Inc. today announced that the Company's phase III pivotal study of glycerol phenylbutyrate (HPN-100), an investigational drug for the treatment of urea cycle disorders (UCDs), met its primary endpoint. The non-inferiority study, conducted under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA) in June 2009, evaluated the ammonia control of glycerol phenylbutyrate as compared to sodium phenylbutyrate (BUPHENYL®).
› Verified 8 days ago
Excell Care Rehabilitation Audiologist Medicare: Not Enrolled in Medicare Practice Location: 2008 W Northside Dr, Clinton, MS 39056 Phone: 601-926-4628 |